CLARIFICATION AND AMENDMENT OF
BIOMS LICENSE AGREEMENT
This agreement made the 13 th day of December 2007
A Delaware corporation doing business at 1199 Madia Street, Pasadena, CA 91103
(“ AutoImmune ”)
BIOMS TECHNOLOGY CORP.
Previously named Rycor Technology Investments Corp., a corporation under the laws of Alberta, doing business at 6030 – 88
Street, Edmonton, Alberta, Canada T6E 6G4
(“ BioMS ”)
WHEREAS AutoImmune and BioMS entered into a Development and License Agreement dated August 1, 2000 (the “ BioMS
License ”) addressing the grant of license to certain Patent Rights in the Field, specifically the administration of native myelin
basic protein (MBP) peptides by injection to non-mucosal sites for the treatment of Multiple Sclerosis;
WHEREAS [* * *]
WHEREAS [* * *]
NOW THEREFORE for the purposes of clarification of the rights and position of BioMS, and in appreciation of the importance
of the Patent Rights and continued existence of the AutoImmune patents, AutoImmune and BioMS hereby Agree.
Superiority of Terms
This Agreement serves to amend the BioMS License. Except as expressly amended hereby, the BioMS License remains in
full force and effect. Where a conflict exists between the terms of this Agreement and the BioMS License, the terms of this
Agreement shall prevail.
Unless otherwise defined within this Agreement, reference shall be made to the definitions and meanings established in
the BioMS License.
[* * *] Represents material which has been redacted and filed separately with the Commission pursuant to a request for
confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
Settlement of Actions
Prosecution of Patents
If BioMS is unable to exercise its rights under Section 5.1.2 of the Agreement in the event AutoImmune elects not to
continue to seek or maintain patent protection on any patent o